JP2013543482A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543482A5 JP2013543482A5 JP2013520218A JP2013520218A JP2013543482A5 JP 2013543482 A5 JP2013543482 A5 JP 2013543482A5 JP 2013520218 A JP2013520218 A JP 2013520218A JP 2013520218 A JP2013520218 A JP 2013520218A JP 2013543482 A5 JP2013543482 A5 JP 2013543482A5
- Authority
- JP
- Japan
- Prior art keywords
- dopamine
- dopa
- agonist
- subject
- usage according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36601510P | 2010-07-20 | 2010-07-20 | |
| US61/366,015 | 2010-07-20 | ||
| PCT/GB2011/051376 WO2012010896A1 (en) | 2010-07-20 | 2011-07-20 | Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013543482A JP2013543482A (ja) | 2013-12-05 |
| JP2013543482A5 true JP2013543482A5 (enExample) | 2014-09-04 |
Family
ID=44583771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013520218A Pending JP2013543482A (ja) | 2010-07-20 | 2011-07-20 | Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20130210786A1 (enExample) |
| EP (1) | EP2595621A1 (enExample) |
| JP (1) | JP2013543482A (enExample) |
| KR (1) | KR20130043197A (enExample) |
| CN (1) | CN103189056A (enExample) |
| AU (1) | AU2011281336B2 (enExample) |
| BR (1) | BR112013001422A2 (enExample) |
| CA (1) | CA2805693A1 (enExample) |
| EA (1) | EA201390070A1 (enExample) |
| MX (1) | MX2013000760A (enExample) |
| SG (1) | SG187090A1 (enExample) |
| WO (1) | WO2012010896A1 (enExample) |
| ZA (1) | ZA201301231B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20110244A7 (es) * | 2011-12-27 | 2013-08-29 | Ct De Investigación Y Desarrollo De Medicamentos Cidem | Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios |
| WO2013183055A1 (en) | 2012-06-05 | 2013-12-12 | Neuroderm Ltd | Compositions comprising apomorphine and organic acids and uses thereof |
| WO2016014242A1 (en) * | 2014-07-21 | 2016-01-28 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods |
| JP2017008044A (ja) * | 2015-06-22 | 2017-01-12 | 学校法人 久留米大学 | ドーパミンシグナル伝達の抑制剤 |
| CN105106230A (zh) * | 2015-08-16 | 2015-12-02 | 南京华宽信息咨询中心 | 一种单胺氧化酶mao抑制剂及其应用 |
| BR112022001595A2 (pt) * | 2019-07-29 | 2022-03-22 | Peptron Inc | Composição farmacêutica para tratamento ou inibição da progressão da discinesia induzida por levodopa |
| US20210100737A1 (en) | 2019-10-03 | 2021-04-08 | Starton Therapeutics, Inc. | Transdermal delivery of dronabinol |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| EP4088721B1 (en) * | 2020-01-08 | 2025-09-17 | Neuroventi | Composition for treating fragile x syndrome or related developmental disorders, comprising lisuride compound as active ingredient |
| US20220047525A1 (en) * | 2020-08-17 | 2022-02-17 | Pike Therapeutics, Inc. | Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids |
| CN115282156A (zh) * | 2022-09-05 | 2022-11-04 | 广东海洋大学 | 知母皂苷元在制备防治帕金森病的药物中的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA985172A (en) | 1972-10-06 | 1976-03-09 | Dushan M. Dvornik | Compositions and methods for reducing blood cholesterol |
| EP0102416A1 (en) | 1982-08-23 | 1984-03-14 | Nutrisearch Company | Blends of egg albumen and whey protein of improved gel strength |
| US4680289A (en) | 1985-06-05 | 1987-07-14 | Progenics, Inc. | Treatment of obesity and diabetes using sapogenins |
| CA2096853A1 (en) * | 1990-11-24 | 1992-05-25 | Anthony Michael Johnson | Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia |
| JP4740426B2 (ja) | 1997-03-17 | 2011-08-03 | ビーティージー・インターナショナル・リミテッド | 治療用組成物 |
| CN1131237C (zh) | 1997-09-26 | 2003-12-17 | 中国人民解放军军事医学科学院放射医学研究所 | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 |
| DK1066042T3 (da) | 1998-03-26 | 2006-12-18 | Phytopharm Plc | Steroidale saponiner til behandling af Alzheimers sygdom |
| GB9923076D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB9905275D0 (en) | 1999-03-08 | 1999-04-28 | Phytopharm Ltd | Treatment of conditions associated with membrane-bound receptors and their function |
| EP1123094B1 (en) | 1998-09-15 | 2007-04-11 | Btg International Limited | Therapeutic compositions (ii) |
| GB2347676A (en) * | 1999-03-08 | 2000-09-13 | Phytopharm Plc | Screening method |
| GB9923078D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB9923077D0 (en) | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| MXPA04009321A (es) * | 2002-03-27 | 2005-01-25 | Phytopharm Plc | Metodos y usos terapeuticos de sapogeninas y sus derivados. |
| US20050130948A1 (en) * | 2002-03-27 | 2005-06-16 | Daryl Rees | Therapeutic methods and uses of sapogenins and their derivatives |
| WO2003082893A2 (en) | 2002-03-27 | 2003-10-09 | Phytopharm Plc | Theraputic methods and uses of sapogenins and their derivatives |
| GB0409567D0 (en) | 2004-04-28 | 2004-06-02 | Phytopharm Plc | Chemical compounds |
| GB0424528D0 (en) | 2004-11-05 | 2004-12-08 | Phytopharm Plc | Chemical compounds |
| US20070041924A1 (en) * | 2005-08-19 | 2007-02-22 | Bioderm Research | Sebum Control Compositions Based on Saponins and Sapogenins |
| EA201190115A1 (ru) * | 2009-01-24 | 2012-02-28 | ФИТОФАРМ ПиЭлСи | Лечение расстройств, опосредованных нейротрофическим фактором |
-
2011
- 2011-07-20 KR KR1020137004015A patent/KR20130043197A/ko not_active Withdrawn
- 2011-07-20 CA CA2805693A patent/CA2805693A1/en not_active Abandoned
- 2011-07-20 WO PCT/GB2011/051376 patent/WO2012010896A1/en not_active Ceased
- 2011-07-20 BR BR112013001422A patent/BR112013001422A2/pt not_active IP Right Cessation
- 2011-07-20 US US13/811,344 patent/US20130210786A1/en not_active Abandoned
- 2011-07-20 SG SG2013003272A patent/SG187090A1/en unknown
- 2011-07-20 EP EP11738032.9A patent/EP2595621A1/en not_active Withdrawn
- 2011-07-20 MX MX2013000760A patent/MX2013000760A/es not_active Application Discontinuation
- 2011-07-20 JP JP2013520218A patent/JP2013543482A/ja active Pending
- 2011-07-20 CN CN2011800412824A patent/CN103189056A/zh active Pending
- 2011-07-20 EA EA201390070A patent/EA201390070A1/ru unknown
- 2011-07-20 AU AU2011281336A patent/AU2011281336B2/en not_active Ceased
-
2013
- 2013-02-18 ZA ZA2013/01231A patent/ZA201301231B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013543482A5 (enExample) | ||
| ES2393211T3 (es) | Uso de 2-aminotetralinas sustituidas para la fabricación de un medicamento para la prevención, alivio y/o tratamiento de diversos tipos de dolor | |
| JP2011522035A5 (enExample) | ||
| AR075625A1 (es) | Tratamiento de trastornos relacionados con la discinesia | |
| JP2009511618A (ja) | 中度から重度のむずむず脚症候群（ｒｌｓ）を治療するためのプラミペキソールの使用 | |
| HRP20171469T1 (hr) | Novi terapijski pristupi u liječenju parkinsonove bolesti | |
| ZA200509779B (en) | Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease | |
| ECSP055569A (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
| CO5190708A1 (es) | Mezcla sinergica para el tratamiento del sindrome de piernas inquietas | |
| AR074826A1 (es) | Regimen de dosificacion para un agonista de los receptores de s1p | |
| NZ595189A (en) | Combination therapy with thiocolchicine derivatives | |
| RU2012142811A (ru) | Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения | |
| JP2005523334A5 (enExample) | ||
| AR075626A1 (es) | Metodos para administrar (4ar,10ar)-1-n- propil-1,2,3,4,4a,5,10,10a- octahidro -benzo (g) quinolin-6,7-diol y sus composiciones farmaceuticas. uso. | |
| Dastgheib et al. | Acute and chronic effects of agomelatine on intravenous penthylenetetrazol-induced seizure in mice and the probable role of nitric oxide | |
| CO5840252A1 (es) | Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada | |
| NZ595376A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
| JP2011526596A5 (enExample) | ||
| JP2019052163A5 (enExample) | ||
| JP2007509146A5 (enExample) | ||
| MX2010006608A (es) | Composiciones farmaceuticas y produccion y uso de las mismas en el tratamiento de neuropatias asociadas con el dolor. | |
| Korczyn | Drug treatment of Parkinson's disease | |
| EA201390653A1 (ru) | Aa антагонисты как усилители когнитивной и моторной функций | |
| JP2010523640A5 (enExample) | ||
| AR076848A1 (es) | Combinacion antitumoral que comprende ave8062 y sorafenib |